BC055004 Inhibitors
Chemical inhibitors of BC055004 function by targeting various kinases that play a crucial role in the signaling pathways essential for the protein's activity. Lapatinib, for instance, is a kinase inhibitor that zeroes in on the EGFR and HER2 tyrosine kinases. By inhibiting these specific kinases, Lapatinib can stifle the downstream signaling pathways in which BC055004 is involved, leading to a reduction in the activity of BC055004 due to weakened signaling through these receptors. Similarly, Sorafenib takes a multi-kinase approach, targeting VEGFR, PDGFR, and RAF kinases. The inhibition of these kinases by Sorafenib disrupts the MAPK/ERK signaling pathway, which is fundamental for BC055004 function, thereby reducing its activity. Sunitinib also falls into this category, with its receptor tyrosine kinase inhibitory action against PDGFR and VEGFR, which interferes with angiogenic pathways and signaling cascades necessary for BC055004 activity.
Furthermore, Erlotinib and Gefitinib specifically inhibit the tyrosine kinase domain of EGFR, a critical player in cellular signaling processes. The inhibition exerted by these drugs can lead to reduced activity in signaling pathways that BC055004 relies on. Dasatinib, with its ability to inhibit BCR-ABL and Src family kinases, and Imatinib, which selectively targets BCR-ABL tyrosine kinase as well as PDGFR and c-Kit, are other examples. These inhibitors disrupt critical signaling pathways that are required for BC055004's functional activity. Crizotinib, which targets ALK, ROS1, and c-Met/HGFR kinases, and Palbociclib, a selective CDK4/6 inhibitor, work by arresting cell cycle progression or inhibiting signaling pathways, respectively, which are imperative for BC055004's activity. Bosutinib and Ponatinib also contribute to the inhibition of BC055004 by targeting Src, Abl, and a broader range of kinases, thereby disrupting the signaling networks upon which BC055004's function depends. Lastly, Vandetanib's inhibition of VEGFR, EGFR, and RET tyrosine kinases impedes signaling pathways crucial for BC055004's activity. Each of these inhibitors, through their unique but often overlapping mechanisms, can lead to the functional inhibition of the BC055004 protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a kinase inhibitor that specifically targets EGFR and HER2 tyrosine kinases. Inhibition of these kinases can impede downstream signaling pathways that BC055004 is involved in, leading to a reduction in BC055004 activity due to diminished signaling through these receptors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases, including VEGFR, PDGFR, and RAF kinases. By inhibiting these kinases, Sorafenib can disrupt signaling pathways such as MAPK/ERK, which may be essential for BC055004 function, thus functionally inhibiting BC055004 through impaired signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor with activity against PDGFR and VEGFR, among others. By inhibiting these kinases, Sunitinib can interfere with the angiogenic pathways and other signaling cascades necessary for BC055004 activity, thereby inhibiting its function. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor which can block the tyrosine kinase activity of EGFR. As EGFR signaling is integral to multiple cellular processes, Erlotinib can disrupt pathways that BC055004 relies on, leading to functional inhibition of BC055004. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib specifically inhibits the tyrosine kinase domain of EGFR. This inhibition can lead to a downstream reduction in signaling pathways that BC055004 is part of, resulting in the functional inhibition of BC055004. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a potent inhibitor of BCR-ABL and Src family kinases. By blocking the activity of these kinases, Dasatinib can disrupt crucial signaling pathways that are necessary for the functional activity of BC055004, hence inhibiting it. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib selectively inhibits BCR-ABL tyrosine kinase, as well as PDGFR and c-Kit. Inhibition of these kinases leads to a blockade of signaling pathways that may be crucial for BC055004's activity, resulting in its functional inhibition. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of CDK4/6, which are critical for cell cycle progression. By inhibiting these kinases, Palbociclib can arrest the cell cycle in a phase that is unfavorable for BC055004 activity, thus functionally inhibiting BC055004. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a multi-target kinase inhibitor, with activity against BCR-ABL and other kinases. Its broad-spectrum kinase inhibition can disrupt signaling networks essential for BC055004's activity, resulting in its functional inhibition. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases. By blocking these kinases, Vandetanib can impede signaling pathways that are essential for the functional activity of BC055004, leading to its inhibition. | ||||||